ArticleEcancermedicalscience2025
Consumer perspective on breast density notification in Australia.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast density is a strong and prevalent risk factor for breast cancer and it significantly reduces the sensitivity of mammography to detect the disease. Inconsistency in breast density notification policy across screening programs in Australia has resulted in significant health promotion challenges, with low awareness and knowledge of breast density as a risk factor and confusion regarding assessment and risk management for women with dense breasts. Australian breast density notification policy has recently been revised and now recommends women be informed of their breast density; however, this policy has not yet been implemented in all BreastScreen programs across the country. The research evidence that supports screening policy and practice does not often incorporate the consumer perspective, which is integral to providing clear recommendations for women with dense breasts. Opportunities for consumer organisations to advance evidence-based health promotion strategies to inform public health policy are limited. This article provides a Consumer Perspective on Breast Density Notification from the Australian Breast Density Consumer Advisory Council. This Perspective provides recommendations for future action to support breast density reporting in Australia. It provides a succinct overview, in lay terms, of what breast density is and its role in breast cancer risk assessment, risk-reduction and early detection. Finally, it addresses concerns relating to individual anxiety after receiving a breast density notification. This perspective aims to inform breast screening policy and practice in Australia. It is a position statement on breast density notification from a consumer perspective, built on lived expertise and research evidence. It builds on increasing evidence that inclusion of a consumer voice within medical research and policy development can improve the quality and relevance of health outcomes and provide more effective research translation and impact. This article advances innovation in breast density research and breast screening policy by prioritising the consumer voice, ensuring research and policy are informed by the lived experiences of consumers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.